Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Harries

Showing results (51-60 of 52) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 52 results.
The Lancet. Oncology|April 30, 2021
Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational studyLeticia Monin, Adam G Laing, Miguel Muñoz-Ruiz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 17, 2018
Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trialP G Corrie, A Marshall, P D Nathan, et al.
Pageof 6

Showing results (51-60 of 52) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 52 results.
The Lancet. Oncology|April 30, 2021
Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational studyLeticia Monin, Adam G Laing, Miguel Muñoz-Ruiz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 17, 2018
Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trialP G Corrie, A Marshall, P D Nathan, et al.
Pageof 6